Celldex Therapeutics $CLDX is doing some pipeline reconstruction, buying out Kolltan Pharmaceuticals in an all-stock deal. Kolltan investors get $62.5 million in Celldex stock up front, along with $172.5 million for a slate of milestones in …
The share price of Celldex Therapeutics, Inc. Institutional investors own 55.99% of the company's stock. Finally, Dimensional Fund Advisors LP increased its position in shares of Celldex Therapeutics by 12.5% in the fourth quarter. …
Zacks Investment Research upgraded Celldex Therapeutics from a "hold" rating to a "buy" rating and set a $3.50 price objective on the stock in a report on Wednesday, May 31st. Looking over the IR ranking chart, the IR got 11 analysts …
Shares of Celldex Therapeutics (CLDX) dipped Tuesday after the stock surged Monday following the company's announcement of positive results of its immunotherapy in treating a certain type of brain tumor.
Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings data on Tuesday, May 9th. 5,370,315 shares …
Celldex has agreed to acquire Kolltan in a stock-for-stock transaction, beginning with an upfront payment of approximately $62.5 million in equity. Celldex also agreed to pay Kolltan shareholders up to $172.5 million in additional payments …
While looking at the Stock's Performance, Celldex Therapeutics, Inc. now shows a Weekly Performance of -19.31%, where Monthly Performance is -25.95%, Quarterly performance is -32.17%, 6 Months performance is -40.76% and …
With this pivotal question firmly in mind, let's consider why the bears might, in fact, be right about this speculative cancer stock. After the late-stage flame out of its brain cancer vaccine Rintega last year, Celldex's antibody-drug conjugate …